Liquid Biopsy for Early Non-small Lung Cancer Detection
This clinical trial will assess the performance of a liquid biopsy assay to identify cancer in indeterminant pulmonary nodules identified by CT screening of high-risk individuals and evaluate the capability of the liquid biopsy assay to monitor response to surgical resection.
Checked against the public recordLast updated Dec 16, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Arizona
- Interventions being studied
- Diagnostic Test: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule; Diagnostic Test: Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection; Diagnostic Test: Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer; Diagnostic Test: Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Indeterminate pulmonary nodule study cohort * Inclusion criteria: Patients undergoing a biopsy of an indeterminate lung nodule by surgical excision, bronchoscopic biopsy or Interventional Radiology directed biopsy * Exclusion criteria: No known concurrent cancer Known lung cancer for surgical resection study cohort * Inclusion criteria: Patients with known non-small cell lung cancer who will have surgical resection for treatment * Exclusion criteria: N/A Healthy volunteer cohort * Inclusion criteria: Healthy persons * Exclusion criteria: No known current cancer or history of cancer within 5 years Benign lung disease cohort * Inclusion criteria: Patients with the following categories of benign lung disease: COPD/emphysema, Granulomatous infection, Interstitial lung disease including pulmonary fibrosis and interstitial lung disease. * Exclusion criteria: N/A
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of ArizonaTucson, Arizona
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 16, 2024. Always confirm current availability with the study team.